IMMX
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.
Immix Biopharma, Inc. (IMMX) is rated C (2.3/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (C+); its weakest is Growth (D). The rating has held at C for 7 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-12 | C+ (2.5) | D (1.3) | C+ (2.7) | C (2.4) | C+ (2.6) | C (2.3) |
| 2026-11-05 | C+ (2.5) | D (1.3) | C+ (2.7) | C+ (2.7) | C+ (2.7) | C (2.4) |
| 2026-10-29 | C+ (2.5) | D (1.3) | C+ (2.7) | B- (3.1) | C+ (2.7) | C (2.5) |
| 2026-10-22 | C+ (2.5) | D (1.3) | C+ (2.8) | B- (3.0) | C+ (2.6) | C (2.4) |
| 2026-10-15 | C+ (2.5) | D (1.5) | C+ (2.8) | C+ (2.8) | C+ (2.6) | C (2.4) |